DFTX
NASDAQDefinium Therapeutics Inc.
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
Price$45.27-0.54 (-1.19%)
01:30 PM07:45 PM
News · 26 weeks85+750%
2026-01-112026-07-05
Mix5390d
- SEC Filings16(30%)
- Insider16(30%)
- Other12(23%)
- Offering4(8%)
- Analyst3(6%)
- Earnings2(4%)
Latest news
25 items- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and
- PRMulti-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient o
- INSIDERChief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- PRA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearIssued on behalf of Helus Pharma™Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026.NEW YORK and TORONTO, June 26, 2026 /CNW/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule. Late-stage psychiatric trials are notoriously hard to fill, which is why a clean enrollment update is meaningful. On June 24, 2026, Helus Pharm
- PRDefinium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced underwritten public offering of 23,676,471 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase 3,088,235 additional common shares, at a public offering price of $34.00 per common share. All of the shares were offered by Definium. The gross proceeds from this offering were $805 million, before deducting underwriting discounts, com
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- SECSEC Form 424B5 filed by Definium Therapeutics Inc.424B5 - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public OfferingDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $700 million. In addition, Definium has granted the underwriters an option for a period of 30 days to purchase up
- ANALYSTNeedham reiterated coverage on Definium Therapeutics with a new price targetNeedham reiterated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $50.00 from $38.00 previously
- PRDefinium Therapeutics, Inc. Announces Proposed Public OfferingDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, Definium intends to grant the underwriters an option for a period of 30 days to purchase up to $75 million of its common shares at the public offering price, less underwriting discounts and commissions. All of the co
- SECSEC Form 424B5 filed by Definium Therapeutics Inc.424B5 - Definium Therapeutics, Inc. (0001813814) (Filer)
- INSIDERChief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive DisorderStudy met primary and all key secondary efficacy endpoints 8.1 point Montgomery-Åsberg Depression Rating Scale (MADRS) placebo-adjusted change from baseline at Week 6 for the primary endpoint (p<0.0001) 7.3 point MADRS placebo-adjusted change from baseline at Week 12, a secondary endpoint (p<0.0001) DT120 ODT was generally well tolerated with no serious adverse events or suicidality signal Company to host webcast today at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced p
DFTX FAQ
5 questionsWhere does DFTX stock trade?
Definium Therapeutics Inc. (DFTX) is listed on NASDAQ.What sector and industry is DFTX in?
Definium Therapeutics Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about DFTX?
Definium Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-06-23. Recent price targets range from $2500.00 to $4900.00.What companies are similar to DFTX?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare DFTX side-by-side with any of them on Quantisnow.How can I track DFTX on Quantisnow?
Quantisnow aggregates Definium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DFTX to receive live email and push alerts on every new disclosure.